Loading
Nosocomial Infections in ICU · Journal article
International Journal of Research in Medical Sciences · July 30, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-centre cross-sectional survey of antimicrobial resistance patterns in Klebsiella pneumoniae and carbapenem-resistant Klebsiella pneumoniae (CRKP) isolated from respiratory tract infection patients in Bangladesh. It reports prevalence of resistance phenotypes and presence of the blaKPC resistance gene but does not assess clinical outcomes, treatment efficacy, or compare interventions, limiting its utility for clinical decision-making.
Cross-sectional surveillance study. Adult patients (≥18 years) clinically diagnosed with lower respiratory tract infections at Sylhet MAG Osmani Medical College, Sylhet, Bangladesh.. n = 153. Sylhet MAG Osmani Medical College, Sylhet, Bangladesh..
Of 153 sputum samples, 66.0% showed bacterial growth; Klebsiella pneumoniae accounted for 20.9% of isolates Among Klebsiella pneumoniae isolates, 25.0% were carbapenem-resistant (CRKP) Of CRKP isolates, 75.0% produced carbapenemase and 50.0% harbored the blaKPC gene
No clinical outcome data reported (mortality, treatment response, length of stay).
Clinicians in similar settings should be aware of elevated CRKP prevalence and carbapenem resistance; the finding that one in every fourth KP isolate was CRKP suggests caution with carbapenem empiric therapy for ESBL-producing KP infections. However, the small number of CRKP isolates (n=8) and lack of clinical outcome data limit recommendations for individual patient management.
Single-centre cross-sectional surveillance study of resistance patterns in clinical isolates; descriptive findings without intervention, control, or hard clinical outcomes, suitable for hypothesis generation rather than clinical decision-making.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians in similar settings should be aware of elevated CRKP prevalence and carbapenem resistance; the finding that one in every fourth KP isolate was CRKP suggests caution with carbapenem empiric therapy for ESBL-producing KP infections. However, the small number of CRKP isolates (n=8) and lack of clinical outcome data limit recommendations for individual patient management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Recently worldwide, carbapenem-resistant Klebsiella pneumoniae (CRKP) infection has attracted a lot of attention because of the scarcity of effective drugs and the severity of the illness as well as the high death rate. This study was conducted to assess the antimicrobial susceptibility profiles and the molecular identification of CRKP isolates that were obtained from patients with lower respiratory tract infection (LRTI) at a tertiary care hospital in Sylhet, Bangladesh. Methods: This cross-sectional study was conducted in the Department of Microbiology at Sylhet MAG Osmani Medical College, Sylhet, from July 2021 to June 2022. A total of 153 sputum samples were collected from adult patients (≥18 years) clinically diagnosed with LRTIs. Data were analyzed using SPSS version 26. Result: Among 153 sputum samples from LRTI patients, 66.0% showed bacterial growth, with Klebsiella pneumoniae accounting for 20.9% of isolates. The mean age was 52.43±17.12 years with male predominance (69.3%). Of the Klebsiella pneumoniae isolates, 25.0% were carbapenem-resistant (CRKP), among which 75.0% produced carbapenemase and 50.0% harbored the KPC gene. Overall isolates showed high resistance to cephalosporins (up to 81.2%) and moderate sensitivity to carbapenems (around 72–75%) and amikacin (56.2%). CRKP isolates demonstrated marked multidrug resistance, with high resistance to most antibiotics, including carbapenems (75.0%). Conclusion: In conclusion, one in every fourth KP isolate was CRKP, which highlighted the need for careful prescription of carbapenems for the therapy of infectious diseases with ESBL-producing KP. Among different genes conferring resistance to carbapenems, only the blaKPC gene was investigated in this study.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.